Prothoracicotropic hormone
Prothoracicotropic hormone (PTTH) was the first insect hormone to be discovered. It was originally described simply as "brain hormone" by early workers such as Stefan Kopeć (1922) and Vincent Wigglesworth (1934), who realized that ligation of the head of immature insects could prevent molting or pupation of the body region excluded from the head if the ligation was performed before a critical age in the lifestage was reached. After a certain point the ligation had no effect and both sections of the insect would molt or pupate. However, implantation of a conspecific brain to a sessile ligated abdomen or an abdomen under diapause would induce molting or pupation. Thus, the brain was originally thought to be the source of the hormone that induces molting in insects.
Flutamide
Flutamide was first synthesized in 1967 by Neri and colleagues at Schering Plough Corporation. It was originally synthesized as a bacteriostatic agent, but was subsequently, and serendipitously found to possess antiandrogen activity. The code name of flutamide during development was SCH-13521. Clinical research of the medication began in 1971, and it was first marketed in 1983, specifically in Chile under the brand name Drogenil and in West Germany under the brand name Flugerel. Flutamide was not introduced in the United States until 1989; it was specifically approved by the U.S. Food and Drug Administration for the treatment of metastatic prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) analogue. The medication was first studied for the treatment of hirsutism in women in women in 1989. It was the first "pure antiandrogen" to be studied in the treatment of hirsutism. Flutamide was the first NSAA to be introduced, and was followed by nilutamide in 1989 and then bicalutamide in 1995.